PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129058
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129058
GMP Plasmid DNA Manufacturing Market size was valued at US$ 278.65 Million in 2025, expanding at a CAGR of 9.5% from 2026 to 2033.
GMP Plasmid DNA Manufacturing is the creation of plasmid DNA in accordance with good manufacturing practice to provide consistent production, control and documentation for clinical trial and commercial biopharmaceutical applications. The procedure generally includes plasmid design/preparation, microbial fermentation, plasmid extraction, purification, concentration, sterile filtration and quality-controlled testing. GMP manufacturing involves complete control of materials, environment, equipment, personnel and process to prevent contamination and to ensure quality, purity, identity, potency and safety of the finished product. GMP-grade plasmid DNA is frequently employed as a key starting material or pharmaceutical ingredient in gene treatments, DNA vaccines, cell therapies and other biotherapeutics.
GMP Plasmid DNA Manufacturing Market- Market Dynamics
Rising number of clinical trials to propel market demand
The increasing number of clinical trials for gene therapies, cell therapies, vaccines and other advanced medicines are driving demand for GMP plasmid DNA as clinical-stage developers need high-quality, regulatory-compliant DNA for viral-vector synthesis and other therapeutic uses. The product launches in 2025 are an example of this tendency. Specifically, in April 2025, ProBio initiated its GMP plasmid DNA manufacturing service at its Hopewell, New Jersey plant, offering clinical-grade plasmid DNA with a targeted delivery timetable of about three months from cell bank to batch release. The company has specifically designed the service to accelerate clinical programs for gene and cell therapies.
Similarly, Aldevron launched its small-scale GMP (ssGMP) plasmid DNA service in July 2025, providing 1 mg to 500 mg quantities that are ideal for early-phase clinical programs such as small patient cohort trials, AAV and lentiviral vector manufacturing, CRISPR-based editing of genes, and transposon therapies. These launches are examples of how the increasing activity in clinical trials is increasing the demand not only for large scale commercial GMP plasmid production but also for flexible smaller volume GMP manufacturing, thus driving the growth of the GMP plasmid DNA manufacturing business.
The Global GMP Plasmid DNA Manufacturing Market is segmented on the basis of Product, Application, Type, and Region.
The market is divided into seven categories based on product: Plasmid DNA, Viral Vectors, Non-viral, Electroporation, Lipid/polymer, Nanoparticles and Others. The Plasmid DNA segment dominates the market. The growth is assisted by the rising number of advanced-therapy programs, which are entering clinical and commercial manufacturing from research and preclinical stages. The companies involved are looking to scale their production, while ensuring the quality of the nucleic acid-based products. Thus, the rising number of pharmaceutical and biotech firms, which are looking to manufacture more high-purity, GMP-grade plasmid DNA, also contributes to the growth of this market.
Moreover, the expansion of viral-vector manufacturing, including such platforms as AAV or lentiviral, is further driving the need for plasmid DNA, as they are often used as part of the process. One more factor which supports the growth of the plasmid DNA manufacturing segment is the companies' investments in the research and development of various fields. For instance, one of the leading manufacturers of plasmid DNA, Aldevron, has announced that it has manufactured more than 165,000 plasmid lots, of which approximately 5,000 are clinical-grade lots. Altogether, they support cell, gene, and mRNA therapy programs, which are either in the clinical trial phases or have been commercialized. Therefore, this trend is expected to support the growth of the GMP plasmid DNA manufacturing market. These launches exemplify that the growing activity in clinical trials is raising the demand not only for large-scale commercial GMP plasmid production but also for flexible, smaller-volume GMP manufacturing, thus fueling the growth of the GMP plasmid DNA manufacturing industry.
The market is divided into four categories based on application: DNA Vaccines, Immunotherapy, Gene Therapy and Others. The DNA Vaccines dominate the market and is likely to maintain its dominance during the forecast period. The main reason behind the growth of the market is the increasing research and clinical development of DNA vaccines, especially for infectious diseases, and cancer. As DNA-vaccine candidates are advancing toward clinical trials, manufacturers are in need of GMP-grade plasmid DNA with high purity, consistency, and regulatory compliance, which increases the demand for specialized plasmid manufacturing services. The research on DNA-plasmid vaccine development is a significant factor supporting the overall plasmid DNA manufacturing market.
GMP Plasmid DNA Manufacturing Market- Geographical Insights
North America holds a prominent market share. Government investment is playing a crucial role in backing such growth. In FY2025, the U.S. National Institutes of Health (NIH) reported a total of about US$48.5 billion. In FY2025, NIH reported US$35.3 billion for competing and noncompeting extramural research awards. These grants help sustain the biomedical research ecosystem that supplies the source of advanced-therapy candidates and clinical programs, which indirectly drives demand for GMP plasmid DNA as medicines enter the clinical development stage.
Government funding also assists advanced cell therapy producers by supporting biomanufacturing infrastructure. The U.S. Department of Commerce announced the Manufacturing USA network financing of US$ 37 million by NIST, including the US$ 14 million yearly allocation for the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The Department of Energy (DOE) sponsored Advanced Cell Therapy manufacturers by fostering domestic biomanufacturing R&D and scale-up activities.
The demand is growing, and industry participants are increasing the investment in the construction of production facilities. For instance, ProBio announced in June 2025 that it would build a 128,000-square-foot GMP plasmid DNA and viral-vector production facility in Hopewell, N.J. The company hopes to satisfy the growing demand for viral vectors by boosting the capacities in the production of cell and gene therapy manufacturers. Hence, the investments in GMP manufacturing facilities along with increasing R&D spending in the biopharmaceutical sector, government-sponsored biomedical research, and augmented clinical pipeline would drive the revenue growth of the GMP plasmid DNA manufacturing market in North America.
US GMP Plasmid DNA Manufacturing Market- Country Insights
The US Capture the largest market share. The major driver driving this growth is the increasing collaborations among the key players in the market, which is increasing the utilization of plasmid DNA for downstream therapeutic manufacture. In May 2025, Wacker Biotech US and Expression Manufacturing forged a strategic relationship to fast-track the development and manufacturing of lentiviral-based gene and cell therapies. Wacker brings their PLASMITEC(R) plasmid DNA platform that features >90% supercoiled pDNA while Expression Manufacturing offers the viral-vector technology. The agreement provides a complete solution from GMP plasmid starting materials to viral-vector production and expands the potential market for plasmid DNA as more gene and cell therapy studies are initiated.
The GMP plasmid DNA manufacturing market is moderately consolidated and competitive, with key CDMOs and plasmid-specific manufacturers vying to secure the majority of the demand by capitalizing on capabilities such as GMP manufacturing capacity, advanced purification technologies, regulatory know-how, turnaround time, scalability, and an ability to offer integrated cell- and gene-therapy services. The key market participants include Aldevron (Danaher), Charles River Laboratories, Thermo Fisher Scientific, Lonza, GenScript ProBio, VGXI, Catalent, AGC Biologics, Kaneka Eurogentec, PlasmidFactory, and WuXi Advanced Therapies. The competition is expected to intensify on the back of an increasing number of players offering end-to-end manufacturing services, which incorporate both plasmid DNA and viral-vector manufacturing and provide comprehensive cell- and gene-therapy solutions to meet the demands of customers at various stages of research and commercialization.
In August 2025, Bionova Scientific (Bionova), a biologics contract development and manufacturing organization (CDMO) and a subsidiary of Asahi Kasei, announced that it has opened a new 10,000-square-foot development and production facility for plasmid DNA (pDNA) in The Woodlands, Texas. The launch of this new facility marks a strategic expansion for the pharmaceutical industry, strengthening the US supply chain for advanced therapeutics. The site will design, develop, and produce research-grade pDNA materials to support the growing cell and gene therapy (CGT) sector.
In August 2025, WACKER and Gearbox Biosciences announced strategic collaboration to advance plasmid DNA manufacturing technologies. The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines.